Board members include industry pioneers Dr. Rick Strassman and Dr. Charles B Nemeroff

AUSTIN, TX –News Direct– Ninnion

Ninnion, a clinical-stage pharmaceutical company focused on developing next-generation psychedelic therapeutics today announced the formation of its Scientific Advisory Board (SAB). The board is composed of key opinion leaders in pharmaceutical development and psychedelics research, including Rick Strassman, MD, Charles B Nemeroff, MD, and chaired by Bill W. Massey, PhD, Ninnion’s Chief Development Officer.

“The level of experience and expertise embodied in our Scientific Advisory Board is absolutely world-class. The SAB members bring a great balance of scientific, drug development and clinical expertise to Ninnion’s programs. Their guidance will be a tremendous asset in navigating the uncharted waters of psychedelic drug development,” said Bill W Massey, Chief Development Officer of Ninnion.

The new SAB is composed of world renowned leaders in the areas of psychedelic research and drug development from top-tier organizations including Johns Hopkins, the Karolinska Institute and University of Texas, Austin. The SAB will work closely with Ninnion leadership, assisting with scientific judgments related to research and pipeline development.

“I’m delighted to serve as a member of Ninnion’s Scientific Advisory Board – this is an opportunity to work together with the best minds in the psychedelic pharmaceutical industry during a time of significant growth and discovery. Collectively we will aim to guide Ninnion through the development of its current pipeline and are committed to following the science as we move forward in developing thoughtful, evidence-based solutions,” said Rick Strassman, MD.

Ninnion’s research and development efforts currently focus on advancing second and third generation psychedelic therapies, which will ultimately empower patients with more accessible and affordable treatment opportunities. The SAB is an integral part of Ninnion’s vision to improve lives and forever change the landscape of today’s psychedelic pharmaceuticals.

“I am honored to be surrounded by such great minds and key opinion leaders contributing to our Scientific Advisory Board. We are bringing the best minds together to create the next generation of psychedelic drug therapies to enhance the lives of patients, starting with those recovering from ischemic stroke.” said Jeremy Caudill, Founder and Chief Executive Officer of Ninnion.

The founding members of the Ninnion Scientific Advisory Board are:

• Rick Strassman, MD, is a world renowned psychiatrist, psychopharmacologist, and pioneer in the advancement of clinical psychedelic research. After 20 years of intermission, Dr. Strassman was the first person in the United States to undertake human studies with psychedelic drugs, with his research on DMT and psilocybin in the early 1990s.
• Charles B. Nemeroff, MD, is an internationally recognized psychiatrist and researcher, specializing in the areas of Neuropsychopharmacology, Psychiatry, mood disorders, and trauma. He serves as the Matthew P. Nemeroff Professor and Chair of the Department of Psychiatry and Behavioral Sciences at the University of Texas at Austin Dell Medical School.
• Ede Frecska, MD, is a prolific author, researcher, and scholar with over 100 peer-reviewed papers and book chapters to his credit. He currently serves as Chief of Department at the National Institute of Psychiatry and Neurology in Budapest.
• Attila Szabo, Ph.D., is a distinguished scholar, researcher, and advocate in the areas of psychoneuroimmunology, immunopsychiatry, biological psychiatry, and the molecular biology of inflammation. His current research focuses on immune-brain interactions in severe mental disorders.
• Patrick Finan, Ph.D., is a trained clinical psychologist and expert in cognitive, behavioral, and affective non-pharmacological mechanisms and treatments for chronic pain. His research focuses on chronic pain and measurement and analysis of dynamic measures of pain and emotion captured in the course of daily life. Dr. Finan is currently the Principal Investigator or Co-Investigator on 8 NIH-funded grants totaling over $20 million.
• Brent Turnipseed, MD, is a dedicated mental health professional and entrepreneur whose work in behavioral health strives to elevate the standard of care for those living with severe mental illness. As a Medical Director and Co-founder of Roots Behavioral Health, Dr. Turnipseed focuses on providing affordable care and expanding access to emerging therapies like ketamine-assisted therapy (KAP) and psychedelic therapeutics.
• Mathias Egermark, MD, is a versatile and agile clinician and healthcare executive with a passion for building high-performing teams in clinical trials and development. Combining years of experience in clinical practice, pharmaceutical development, and business leadership, Dr. Egermark has distinguished himself as a leader in managing cross-functional teams in global settings.
• Jair Soares, MD, Ph.D., is a well-recognized researcher, academic, and clinician who has published over 300 peer-reviewed articles and book chapters in the field of psychiatry. He has been the recipient of numerous awards, academic and non-academic honors & appointments, including over two dozen awards for his work in the field of medicine and psychiatry. He is a board-certified psychiatrist and serves as Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at UTHealth Houston Medical School, and director for the Center of Excellence on Mood Disorders.

To find out more about Ninnion’s Scientific Advisory Board and or to view a full list of its members, visit www.ninnion.com/.

About Ninnion

Headquartered in Austin, Texas, Ninnion is a pharmaceutical company on a mission to build a fully integrated pharmaceutical psychedelics eco-system leveraging the latest AI drug discovery, development, cGMP manufacturing, commercialization, patient clinics and specialty pharmacy distribution network designed for the next frontier of psychedelic medicine. Focused on the payer-reimbursed market, Ninnion has begun developing a pipeline of next generation psychedelic therapies with a clinical focus on brain injury, chronic pain, inflammation, and addiction disorders. To learn more, visit www.ninnion.com.

Contact Details

Jive PR + Digital

Ashley Areeda

+1 734-891-4013

[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

In His Role, Mr. Hackney Will Focus on International Initiatives and Affairs as One World Seeks to Expand its Global Platform of Sustainable Hemp and Cannabis Solutions

Mr. Hackney Joins Recently Appointed Board Chair Minyon Moore in Strengthening Company’s Advisory Board; Both Will Drive One World’s Global Expansion Efforts into New Markets and Sectors

LAS VEGAS, Jan. 25, 2022 (GLOBE NEWSWIRE) — One World Products, Inc. (OTC: OWPC) (“One World” or the “Company”), the largest Black-controlled, fully-licensed cannabis and hemp producer in Colombia, today announces the addition of Jim Hackney to its Advisory Board. Mr. Hackney will serve as Chief Global Strategist on the Advisory Board and will be instrumental in leading the Company’s international initiatives as One World seeks to expand its global platform of sustainable hemp and cannabis solutions.

Mr. Hackney will also serve as the lead advisor for One World’s continued build-out of prominent investment partnerships globally, and joins recently appointed Advisory Board Chair Minyon Moore. Both Mr. Hackney and Ms. Moore will be instrumental in driving One World’s expansion efforts into multiple industries and markets. Ms. Moore will also lead the Company’s efforts evaluating various global supplier diversity initiatives like the recent Stellantis National Black Supplier Development Program. One World Products was recently selected by Stellantis N.V., one of the world’s largest automotive manufacturers with brands such as Chrysler, Dodge, Fiat, Maserati, and Peugeot – to develop and supply hemp-based bioplastic solutions for interior and exterior components as part of the National Black Supplier Development Program. The Program is a joint initiative of Stellantis and the National Business League (NBL) and is the nation’s first black supplier development program.

“The addition of Jim Hackney to our Advisory Board as Chief Global Strategist is a tremendous accomplishment for One World. Jim has been a leader, duly representing the United States for more than 40 years in several capacities in the world of international investment, finance and trade,” commented Isiah Thomas, Executive Chairman and CEO of One World. “Jim’s experience and counsel in international trade, business, and finance will be invaluable as we tackle the challenges of becoming a leader in the global hemp and cannabis economy,” continued Mr. Thomas.

“The global opportunities for commercial hemp and cannabis have only just begun to be realized. I believe the recently-announced initiative with Stellantis is an early example of the potential applications for commercial hemp in industries around the world,” stated Mr. Hackney. “I am proud to be representing One World in expanding their sustainable hemp and cannabis platform into new geographies and sectors. I believe their vertically-integrated business model and their environmentally- and socially-focused approach is distinctive, and demonstrates the leadership that we will only continue to underscore moving forward,” continued Mr. Hackney.

Mr. Hackney is a Principal and Co-Founder of Inergix Corporation, a global consulting and advisory services firm established in 2014 to service clients in the energy, healthcare, technology and security industries. As of November 1, 2021, Mr. Hackney has also assumed the role of Chief Global Strategy and Investment Officer of ISIAH INTERNATIONAL, a holding company with domestic and foreign interests in a diversified portfolio of companies founded by the legendary Hall of Fame basketball great Isiah Lord Thomas III.

Mr. Hackney served in the Administrations of President Jimmy Carter and President Bill Clinton. During the Clinton Administration, he served as Counselor to the Secretary of Commerce, Ronald H. Brown. As one of the Secretary’s closest and most trusted advisers, Mr. Hackney helped to devise and implement the Commercial Diplomacy Program, which was principally responsible for the awarding of $50 billion in infrastructure contracts to U.S. firms by the governments of Saudi Arabia, Mexico, China, India, Brazil, Argentina, Turkey, Egypt and South Africa. In addition, Mr. Hackney co-managed programs that provided aid, business opportunities, and access for small businesses and women- and minority-owned businesses to domestic and international markets.

As a U.S. State Department legal adviser during the Carter years, Mr. Hackney negotiated several bilateral investment agreements, including those with China, Egypt, Morocco, Jamaica, Panama and Malaysia. His portfolio also included advising the State Department’s policy officers on legal matters involving the World Bank, the International Monetary Fund (IMF), U.S. Export Import Bank (EXIM), the Overseas Private Investment Corporation (OPIC) and the US Committee on Foreign Investment in the U.S. (CFIUS).

During his career, Mr. Hackney has also been a member of two highly recognized global law firms. During his tenure at White and Case, he was a member of the firm’s Sovereign Practice Group. In this capacity, he advised the Governments of Egypt, Morocco, Jordan, Turkey and Indonesia on their financial and commercial transactions with the OECD member states, the World Bank, the IMF and the major global banking institutions. In addition, Mr. Hackney provided legal counsel and advice on a range of infrastructure project financings, foreign military sales transactions, and privatizations of state-owned enterprises.

In addition to his international corporate practice, throughout his career, Mr. Hackney has been engaged in substantial pro bono legal work on behalf of the Democratic National Committee, the Lawyers Committee for Civil Rights Under Law, Trans Africa, the American Society of International Law, the Robert F. Kennedy Human Rights Foundation and the Center for Law and Social Policy.

Mr. Hackney holds a B.A. in Political History and a J.D. law degree from the University of Pennsylvania. He has served on the boards of public and private companies, and nonprofit organizations.

About One World Products
One World Products is the largest Black-controlled, fully licensed cannabis and hemp producer with offices in Las Vegas, Nevada and offices and operations in Bogota and Popayan, Colombia. One World Products planted its first crop of cannabis in 2018 at its cultivation site in Popayan, Colombia, and began harvesting commercially in the first quarter of 2020. The company expects to supply its global clients with the highest quality industrial and commercial applications for cannabis, hemp and hemp products, including derivatives in crude oil, distillate, and isolate forms with industrial scale production to serve global cannabis and hemp demand. Its products will be produced and tested to GAP, GMP and ISO standards.

One World Products was recently selected by Stellantis N.V., one of the world’s largest automotive manufacturers with brands such as Chrysler, Dodge, Fiat, Maserati, and Peugeot – to develop and supply hemp-based bioplastic solutions for interior and exterior components.

As its name suggests, One World is also focused on environmental, social and governance (ESG) standards, with particular emphasis on its impact on the environment as well as ensuring that its employees, particularly those within its Colombia operations, are valued and recognized for their contributions, while simultaneously maintaining stewardship over their indigenous land.

Contact:

CORE IR
Matt Blazei
516-386-0430
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Igal Sudman, Chairman and Chief Executive Officer
Ayurcann Holdings Corp.
Tel: 905-492-3322 x30
Email: [email protected]

Investor Relations:
Ryan Bilodeau
Tel: 416-910-1440
Email: [email protected]

About Ayurcann Holdings Corp.
Ayurcann is a leading post-harvest solution provider with a focus on providing and creating custom processes and pharma grade products for the adult use and medical cannabis industry in Canada. Ayurcann is focused on becoming the partner of choice for leading Canadian cannabis brands by providing best-in-class, proprietary services including ethanol extraction, formulation, product development and custom manufacturing.

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements, including but not limited to statements relating to the Company’s expansion plans and future production capacity. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include, but are not limited to, failure to obtain regulatory approval, ability to increase production at the Company’s facilities, the continued availability of capital and financing, and general economic, market or business conditions. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the statements will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, Further, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. Public health crises, including the ongoing novel coronavirus (COVID-19) pandemic, could have significant economic and geopolitical impacts that may adversely affect the Company’s business, financial condition and/or results of operations.  The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements.